Serbian company NeoMedica from Nis will soon, the first in the region and one of the few in the world, begin production of tests for the new corona virus

According to the owner and director of NeoMedica and the president of the Medical Device Manufacturers Group of Serbia's Chamber of Commerce, Sasa Trickovic: - spatial, personnel and conditions concerning the equipment at our disposal. With the great support that the Serbian Chamber of Commerce has provided us from the beginning, we expect to start producing 1,500 tests a day in the next two to three weeks, ”

Serbian Chamber of Commerce President Marko Cadez announced that at the initiative of Nectar, the Serbian Chamber of Commerce will divert five million dinars to Niš, which Nectar has paid into the humanitarian account of PKS for donations.

NeoMedica already manufactures reagents and apparatus in the fields of hematology, biochemistry and urine analysis, which are used by laboratories and hospitals, not only domestically but worldwide. In two decades of work, from a small family business, it has become one of the leading domestic manufacturers of in vitro diagnostic medical devices and one of the largest exporters in its industry, a company investing in business expansion, its expert teams, application of world standards and the development of new products.

"We recognized the opportunity to penetrate the immunology market and a fully automated monotest, the Naiss immunochemical analyzer, was created using the 'one cartridge-one test-one patient' model," Trickovic explains.

This concept, he said, is unique globally and allows healthcare professionals a reliable and maximally efficient diagnostic system. This, he notes, was also recognized in 2018 by the Innovation Fund, which with a large grant supported the development of tests for the detection and quantification of viruses, infectious diseases, hormones, tumor markers. After the epidemic is over, tests from the Nis factory will be able to be used, both here and abroad, to examine a large sample of the population to determine whether the vaccination conditions are met.

Newsletter

За више информација о актуелностима из области иновација, пријавите се за наш Newsletter.

Успешно сте се пријавили.

Већ сте пријављени.

Ова адреса се не може пријавити.